EU Launches Safety Review Of Pseudoephedrine Over New Ischemia Concerns
Companies Are To Provide Comments By 24 March
Executive Summary
The French regulator says that the safety issues associated with pseudoephedrine-containing medicines, and the fact that they are indicated for "benign, non-life threatening and self-resolving conditions," calls their benefit-risk balance into question.
You may also be interested in...
French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine
The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said today.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.